Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHRH1SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC6A2
The experimentally established mechanism targets of Orphenadrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.71 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.71 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.71 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.71 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.71 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.71 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.71 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.71 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.71 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.52 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.52 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.52 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orphenadrine SCHEMBL119470 | 1.00 | KDM4E (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL29369316 | 1.00 | KDM4E (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Diphenhydramine SCHEMBL322306 | 0.90 | LMNA (0.80) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Diphenhydramine SCHEMBL7914760 | 0.88 | LMNA (0.79) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Diphenhydramine SCHEMBL5678067 | 0.88 | LMNA (0.79) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL10840686 | 0.87 | LMNA (0.76) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL10840687 | 0.87 | LMNA (0.75) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL10840564 | 0.84 | LMNA (0.71) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL28727 | 0.84 | SLC6A2 (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL119471 | 0.84 | SLC6A2 (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| EP-4735456-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4638455-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638440-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4634180-A1 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | Gasherbrum Bio, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-1827481-A2 | A COMPOSITION COMPRISING PP FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Aditech Pharma AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1750753-A1 | A COMPOSITION COMPRISING PYY FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Aditech Pharma AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006111169-A1 | PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG | GASTROTECH PHARMA A/S (DK) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006063596-A2 | A COMPOSITION COMPRISING PP FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ADITECH PHARMA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005110457-A2 | TREATMENT OF EATING DISORDERS AND INDUCTION OF LIPOLYSIS | ADITECH PHARMA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110467-A1 | A COMPOSITION COMPRISING PYY FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ADITECH PHARMA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | SLC6A2 2241/4885HRH1 410/4885GRIN2D 3892/4885 |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | SLC6A2 1912/4885HRH1 703/4885GRIN2D 3279/4885 |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | SLC6A2 1183/4885HRH1 396/4885GRIN2D 2633/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | SLC6A2 334/4885HRH1 1531/4885GRIN2D 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.